Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 25 Researches
7.8
USERS' SCORE
Good
Based on 1 Review
8.4
Top Medical Research Studies
9
We investigated the effects of a daily dose of 300 mg vitamin E for treating metabolic dysfunction-associated steatohepatitis (MASH). In our study, 124 non-diabetic individuals were randomly assigned to either vitamin E or a placebo.
The results showed that 29.3% of those on vitamin E had improvements in liver histology, compared to just 14.1% in the placebo group. While we saw significant benefits in liver conditions like steatosis and inflammation, 12 serious adverse events were reported, although they weren’t linked to the treatment.
Overall, our findings indicate that vitamin E may offer meaningful improvements in liver health for those with MASH.
The results showed that 29.3% of those on vitamin E had improvements in liver histology, compared to just 14.1% in the placebo group. While we saw significant benefits in liver conditions like steatosis and inflammation, 12 serious adverse events were reported, although they weren’t linked to the treatment.
Overall, our findings indicate that vitamin E may offer meaningful improvements in liver health for those with MASH.
Read More
9
We analyzed multiple clinical trials to understand how vitamin E impacts liver disease, specifically metabolic dysfunction-associated steatotic liver disease (MASLD).
Our findings reveal that vitamin E significantly improves key liver markers like alanine aminotransferase (ALT) and aspartate aminotransferase (AST), suggesting it may help reduce liver inflammation.
Additionally, vitamin E enhances liver histology by decreasing fat accumulation and inflammation. However, it does not appear to affect liver fibrosis.
Overall, vitamin E could be a valuable option for managing liver health in MASLD patients.
Our findings reveal that vitamin E significantly improves key liver markers like alanine aminotransferase (ALT) and aspartate aminotransferase (AST), suggesting it may help reduce liver inflammation.
Additionally, vitamin E enhances liver histology by decreasing fat accumulation and inflammation. However, it does not appear to affect liver fibrosis.
Overall, vitamin E could be a valuable option for managing liver health in MASLD patients.
Read More
We conducted a study to explore the effects of high-dose coenzyme Q10 supplementation on patients suffering from liver disease related to metabolic dysfunction, known as Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD). In a well-structured double-blind, placebo-controlled trial with sixty participants, half received 240 mg of coenzyme Q10 daily, while the other half received a placebo for six months.
Our findings were promising. Patients taking coenzyme Q10 showed significant improvements in various aspects of their health related to liver functions and cardiovascular health. Specifically, we observed a reduction in liver fat content, as assessed by the controlled attenuation parameter, along with better blood vessel function and heart performance. For instance, the flow-mediated dilation of the brachial artery and the coronary flow reserve significantly improved in those receiving the supplement.
Interestingly, while the placebo group did not show any improvements during the six-month period, the coenzyme Q10 group demonstrated a clear correlation between the reduction in liver fat and enhancements in micro- and macrovascular functions. These results suggest that coenzyme Q10 could potentially be a beneficial treatment option for those battling MASLD.
Our findings were promising. Patients taking coenzyme Q10 showed significant improvements in various aspects of their health related to liver functions and cardiovascular health. Specifically, we observed a reduction in liver fat content, as assessed by the controlled attenuation parameter, along with better blood vessel function and heart performance. For instance, the flow-mediated dilation of the brachial artery and the coronary flow reserve significantly improved in those receiving the supplement.
Interestingly, while the placebo group did not show any improvements during the six-month period, the coenzyme Q10 group demonstrated a clear correlation between the reduction in liver fat and enhancements in micro- and macrovascular functions. These results suggest that coenzyme Q10 could potentially be a beneficial treatment option for those battling MASLD.
Read More
Most Useful Reviews
7.5
Improved liver levels
2 people found this helpful
It works. My husband was diagnosed with fatty liver disease, and a study indicated that several supplements, including CoQ10, could help control his levels. He’s been taking this for two months, and his labs show improvement.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 25 Researches
7.8
- All Researches
9
We investigated the effects of a daily dose of 300 mg vitamin E for treating metabolic dysfunction-associated steatohepatitis (MASH). In our study, 124 non-diabetic individuals were randomly assigned to either vitamin E or a placebo.
The results showed that 29.3% of those on vitamin E had improvements in liver histology, compared to just 14.1% in the placebo group. While we saw significant benefits in liver conditions like steatosis and inflammation, 12 serious adverse events were reported, although they weren’t linked to the treatment.
Overall, our findings indicate that vitamin E may offer meaningful improvements in liver health for those with MASH.
The results showed that 29.3% of those on vitamin E had improvements in liver histology, compared to just 14.1% in the placebo group. While we saw significant benefits in liver conditions like steatosis and inflammation, 12 serious adverse events were reported, although they weren’t linked to the treatment.
Overall, our findings indicate that vitamin E may offer meaningful improvements in liver health for those with MASH.
Read More
9
We examined how vitamin E supplementation affects liver disease in children with Gaucher disease. In this clinical trial, 40 pediatric patients receiving enzyme replacement therapy were divided into two groups: one received vitamin E for six months and the other did not.
The results showed that vitamin E significantly reduced oxidative stress markers and improved liver health, as indicated by decreases in liver and spleen volumes and stiffness. This suggests that vitamin E can enhance treatment efficacy for Gaucher disease, making it a safe and beneficial addition to existing therapies.
The results showed that vitamin E significantly reduced oxidative stress markers and improved liver health, as indicated by decreases in liver and spleen volumes and stiffness. This suggests that vitamin E can enhance treatment efficacy for Gaucher disease, making it a safe and beneficial addition to existing therapies.
Read More
9
We analyzed multiple clinical trials to understand how vitamin E impacts liver disease, specifically metabolic dysfunction-associated steatotic liver disease (MASLD).
Our findings reveal that vitamin E significantly improves key liver markers like alanine aminotransferase (ALT) and aspartate aminotransferase (AST), suggesting it may help reduce liver inflammation.
Additionally, vitamin E enhances liver histology by decreasing fat accumulation and inflammation. However, it does not appear to affect liver fibrosis.
Overall, vitamin E could be a valuable option for managing liver health in MASLD patients.
Our findings reveal that vitamin E significantly improves key liver markers like alanine aminotransferase (ALT) and aspartate aminotransferase (AST), suggesting it may help reduce liver inflammation.
Additionally, vitamin E enhances liver histology by decreasing fat accumulation and inflammation. However, it does not appear to affect liver fibrosis.
Overall, vitamin E could be a valuable option for managing liver health in MASLD patients.
Read More
9
We investigated how gamma-tocotrienol (γ-T3), a form of vitamin E, impacts the growth of liver cancer cells. Our study involved treating HepG2 cells, which overexpress a specific protein (HSD17B4), with vitamin E and watching how it changes their behavior.
We found that γ-T3 not only slowed down cell growth but also promoted cell death in these problematic liver cells. Importantly, the effect was not due to changing HSD17B4 expression directly, but by inhibiting its activity instead.
Overall, our results suggest that γ-T3 could be a promising treatment option for liver cancer, especially in targeting cancer growth pathways.
We found that γ-T3 not only slowed down cell growth but also promoted cell death in these problematic liver cells. Importantly, the effect was not due to changing HSD17B4 expression directly, but by inhibiting its activity instead.
Overall, our results suggest that γ-T3 could be a promising treatment option for liver cancer, especially in targeting cancer growth pathways.
Read More
9
We explored the potential of coenzyme Q10 (CoQ) in combination with selenium (Se) to improve liver health in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). Our recent study involved male C57BL/6J mice fed a methionine choline-deficient diet, known to induce liver problems. The treatment groups received CoQ, Se, or both substances together for four weeks, while a control group received a methionine choline-sufficient diet.
The results revealed that both CoQ and Se, particularly when used in combination, significantly reduced liver inflammation, fibrosis, and fat accumulation. We observed that these antioxidants alleviated oxidative stress and decreased markers of lipid peroxidation, alongside improving liver enzyme levels in the mice's blood. Importantly, the combination therapy also appeared to support cellular health by regulating proteins related to a specific type of cell death known as ferroptosis.
Our findings suggest that CoQ, especially in tandem with selenium, has therapeutic potential for managing liver diseases like MASH. This research opens doors for deeper investigations into antioxidant treatments for liver health, showcasing how we might leverage natural compounds for better outcomes in metabolic liver conditions.
The results revealed that both CoQ and Se, particularly when used in combination, significantly reduced liver inflammation, fibrosis, and fat accumulation. We observed that these antioxidants alleviated oxidative stress and decreased markers of lipid peroxidation, alongside improving liver enzyme levels in the mice's blood. Importantly, the combination therapy also appeared to support cellular health by regulating proteins related to a specific type of cell death known as ferroptosis.
Our findings suggest that CoQ, especially in tandem with selenium, has therapeutic potential for managing liver diseases like MASH. This research opens doors for deeper investigations into antioxidant treatments for liver health, showcasing how we might leverage natural compounds for better outcomes in metabolic liver conditions.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Improved liver levels
2 people found this helpful
It works. My husband was diagnosed with fatty liver disease, and a study indicated that several supplements, including CoQ10, could help control his levels. He’s been taking this for two months, and his labs show improvement.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Hua S, Zhong W, Sha Y, Ma M, Ge S. Negative association of composite dietary antioxidant index with risk of hepatic fibrosis in individuals underwent cholecystectomy: a cross-sectional study. Sci Rep. 2025;15:9040. doi:10.1038/s41598-025-93782-z
- Song Y, Ni W, Zheng M, Sheng H, Wang J, et al. Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study. Cell Rep Med. 2025;6:101939. doi:10.1016/j.xcrm.2025.101939
- Palencia-Campos A, Ruiz-Cañas L, Abal-Sanisidro M, López-Gil JC, Batres-Ramos S, et al. Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis. J Nanobiotechnology. 2024;22:795. doi:10.1186/s12951-024-03010-5
- Dong JX, Jiang LL, Liu YP, Zheng AX. Association between composite dietary antioxidant index and metabolic dysfunction-associated fatty liver disease: a cross-sectional study from NHANES. BMC Gastroenterol. 2024;24:465. doi:10.1186/s12876-024-03556-6
- Sahin A, Demirel-Yalciner T, Sozen E, Ozer NK. Protective effect of alpha-tocopherol on lipogenesis and oxysterol production in hypercholesterolemia-induced nonalcoholic steatohepatitis. Free Radic Res. 2024;58:630. doi:10.1080/10715762.2024.2421173
- Wen H, Deng H, Yang L, Li L, Lin J, et al. Vitamin E for people with non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2024;10:CD015033. doi:10.1002/14651858.CD015033.pub2
- Adly AAM, Ismail EAR, Ibrahim FA, Atef M, El Sayed KA, et al. A 6-month randomized controlled trial for vitamin E supplementation in pediatric patients with Gaucher disease: Effect on oxidative stress, disease severity and hepatic complications. J Inherit Metab Dis. 2025;48:e12792. doi:10.1002/jimd.12792
- Al-Baiaty FDR, Ishak S, Mohd Zaki F, Masra F, Abdul Aziz DA, et al. Assessing the efficacy of tocotrienol-rich fraction vitamin E in obese children with non-alcoholic fatty liver disease: a single-blind, randomized clinical trial. BMC Pediatr. 2024;24:529. doi:10.1186/s12887-024-04993-8
- Chee NM, Sinnanaidu RP, Chan WK. Vitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis. J Gastroenterol Hepatol. 2024;39:2545. doi:10.1111/jgh.16723
- Li J, Yang Y, Huang J, Ye D, Sun X, et al. A Comprehensive Investigation of Dietary Micronutrient Intakes and Risk of Alcoholic Liver Disease. J Nutr. 2024;154:2909. doi:10.1016/j.tjnut.2024.07.012
- Wang X, Liang X, Zhang N, Wang Y, Hu M, et al. Gamma-tocotrienol Inhibits Proliferation and Growth of HSD17B4 Overexpressing HepG2 Liver Cancer Cells. Curr Cancer Drug Targets. 2025;25:170. doi:10.2174/0115680096319171240623091614
- Albert SG, Wood EM. FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD). J Diabetes Complications. 2024;38:108777. doi:10.1016/j.jdiacomp.2024.108777
- Akman AU, Erisgin Z, Turedi S, Tekelioglu Y. Methotrexate-induced hepatotoxicity in rats and the therapeutic properties of vitamin E: a histopathologic and flowcytometric research. Clin Exp Hepatol. 2023;9:359. doi:10.5114/ceh.2023.132251
- Malandris K, Papandreou S, Vasilakou D, Kakotrichi P, Sarakapina A, et al. Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta-analysis. J Gastroenterol Hepatol. 2024;39:1219. doi:10.1111/jgh.16559
- Choi H, Choi J, Go Y, Chung J. Coenzyme Q and Selenium Co-Supplementation Alleviate Methionine Choline-Deficient Diet-Induced Metabolic Dysfunction-Associated Steatohepatitis in Mice. Nutrients. 2025;17. doi:10.3390/nu17020229
- Aydin I, Erisgin Z, Cinar E, Barak MZ, Tekelioglu Y, et al. Should combined MTX and CoQ10 use be reconsidered in terms of steatosis? A biochemical, flow cytometry, histopathological experimental study. Drug Chem Toxicol. 2024. doi:10.1080/01480545.2024.2442660
- Vrentzos E, Ikonomidis I, Pavlidis G, Katogiannis K, Korakas E, et al. Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with metabolic-dysfunction associated steatotic liver disease: a randomized double-blind, placebo-controlled trial. Cardiovasc Diabetol. 2024;23:245. doi:10.1186/s12933-024-02326-8
- Yoladi FB, Palabiyik-Yucelik SS, Bahador Zirh E, Halici Z, Baydar T. Effects of idebenone and coenzyme Q10 on NLRP3/caspase-1/IL-1β pathway regulation on ethanol-induced hepatotoxicity in rats. Drug Chem Toxicol. 2024;47:1205. doi:10.1080/01480545.2024.2351191
- Hooshangi Shayesteh MR, Hami Z, Chamanara M, Parvizi MR, Golaghaei A, et al. Evaluation of the protective effect of coenzyme Q on hepatotoxicity caused by acute phosphine poisoning. Int J Immunopathol Pharmacol. 2024;38:3946320241250286. doi:10.1177/03946320241250286
- Akbel E, Kucukkurt I, Ince S, Demirel HH, Acaroz DA, et al. Investigation of protective effect of resveratrol and coenzyme Q against cyclophosphamide-induced lipid peroxidation, oxidative stress and DNA damage in rats. Toxicol Res (Camb). 2024;13:tfad123. doi:10.1093/toxres/tfad123
- Heidari-Kalvani N, Alizadeh-Fanalou S, Yarahmadi S, Fallah S, Alipourfard I, et al. Investigation of the effects of catharanthine and Q10 on Nrf2 and its association with MMP-9, MRP1, and Bcl-2 and apoptosis in a model of hepatocellular carcinoma. Naunyn Schmiedebergs Arch Pharmacol. 2024;397:2507. doi:10.1007/s00210-023-02767-0
- Nalbant MA, Eroğlu O. Effects of Pyrroloquinoline Quinone (PQQ) and Coenzyme Q10 on Mitochondrial Genes, MitomiRs and Cellular Properties in HepG2 Cell Line. Cell Mol Biol (Noisy-le-grand). 2023;69:60. doi:10.14715/cmb/2023.69.4.9
- Ardekani A, Tabrizi R, Maleki E, Bagheri Lankarani K, Heydari ST, et al. Effects of coenzyme Q10 supplementation on lipid profiles and liver enzymes of nonalcoholic fatty liver disease (NAFLD) patients: A systematic review and meta-analysis of randomized controlled trials. Food Sci Nutr. 2023;11:2580. doi:10.1002/fsn3.3315
- Hibino M, Maeki M, Tokeshi M, Ishitsuka Y, Harashima H, et al. A system that delivers an antioxidant to mitochondria for the treatment of drug-induced liver injury. Sci Rep. 2023;13:6961. doi:10.1038/s41598-023-33893-7
- He X, Liang SM, Wang HQ, Tao L, Sun FF, et al. Mitoquinone protects against acetaminophen-induced liver injury in an FSP1-dependent and GPX4-independent manner. Toxicol Appl Pharmacol. 2023;465:116452. doi:10.1016/j.taap.2023.116452
